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Glomerular hemodynamics and eicosanoid synthesis in a rat model of
IgA nephropathy. We sought to study glomerular pathophysiology in a
model of IgA nephropathy (IgAN). Preliminary experiments with oral
immunization indicated that Lewis rats had higher IgA levels and
IgA/IgG ratios than Wistar, Fischer or Sprague-Dawley rats. Six groups
of Lewis rats were studied: four continuously orally immunized for
eight weeks with bovine gamma globulin (BGG) in the drinking water,
the other two non-immunized controls. Groups of immunized rats were
treated with a thromboxane receptor antagonist (SQ 29,485) and/or a
thromboxane synthase inhibitor (UK 38,485). After systemic challenge,
microscopic hematuria was present in 84% of immunized rats not given
anti-thromboxane drugs versus 18% of non-immunized rats (P < 0.01).
Immunized rats showed predominantly IgA glomerular deposits with
lesser IgG and C3, and produced more glomerular thromboxane than
controls, but no significant increase in prostaglandin E2. Immunized
rats also had reduced GFR and RPF, but not a reduced filtration
fraction, compared to controls. Thromboxane synthase inhibitor dimin-
ished glomerular thromboxane and increased prostaglandin E2 in im-
munized rats. Anti-thromboxane therapy reduced hematuna and appar-
ently re-established the RPF but not the GFR in immunized rats,
yielding a reduced filtration fraction. We propose that increased throm-
boxane, in concert with mesangial contraction that is unaffected by
anti-thromboxane drugs, contributes to the pathophysiology in this
model of IgAN.
As the most common form of glomerulonephritis worldwide,
IgA nephropathy (IgAN) has received growing attention in the
twenty years since it was first recognized [1—4]. Clinicopatho-
logic studies have characterized the disease as a mesangio-
pathic glomerulonephritis with microscopic or macroscopic
hematuria, Histologic appearance, impairment of renal func-
tion, and protein excretion are variable. Long-term follow-up
indicates that the disease has the potential for progression to
glomerulosclerosis. While portents of prognosis have been
identified, none is highly reliable, particularly for an individual
patient. Moreover, little is known about the etiology, pathogen-
esis and pathophysiology of the disease.
Several animal models of IgAN exist, each emphasizing
distinct aspects [51. Injection of IgA immune complexes into
mice elicits many of the features of the human disease [6]. The
capacity of an animal to mount an immune response in which
IgA is prominent, whether due to the nature of the antigen [7] or
the route of its presentation [81, is an important determinant,
which is partly under genetic control [9]. Spontaneous disease
can also occur in mice [10]. In experimental IgAN, the size and
electrostatic charge of the antigen can influence the character of
the immune deposits [7, 11], just as they do in other forms of
experimental glomerulonephritis [12—141.
In spite of obvious gaps in our understanding of the immu-
nologic aspects of IgAN, there has been progress, in part due to
an interplay between clinical, immunologic and experimental
studies [1—4, 15]. Pathophysiologic studies in animals could
serve as a guide to more analytic studies of pathophysiology in
IgAN patients. Physiologic measurements are difficult in mice,
and would be facilitated in rats; however, the few models of
IgAN that have been established in rats are secondary to severe
hepatobiiary derangements [16, 17].
We reasoned that development of a model of primary IgAN in
rats would be of value for pathophysiologic investigation.
Accordingly, we attempted to induce IgAN in rats via an
immunization protocol that we adapted from our previous
mouse model [8] and that we consider relevant to its pathogen-
esis in humans: that is, protracted mucosal immunization. In
these studies, we focused on the potential relationships among
hematuria, proteinuria and glomerular hemodynamics, since
these are the functional changes most consistently observed in
patients, and best associated with prognosis [1—4]. We consid-
ered these functional changes in the context of glomerular
synthesis of prostaglandin E2 and thromboxane, since these
lipid mediators have been emphasized as potentially important
in glomerulonephritis, especially in altered glomerular hemody-
namics [18—33]. Experimental pharmacologic agents, aimed at
interfering with the synthesis or effect of thromboxane in
glomeruli, ameliorate hematuria and decrements in RPF in rats
with IgAN. Accordingly, we propose that alterations in the
proportion of vasoconstrictor and anti-constrictor eicosanoids
contribute to glomerular dysfunction in IgAN.
Methods
Immunization protocols
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For pilot experiments, Lewis, Wistar, Fischer and Sprague-
Dawley rats, all 200 g males (Charles River Breeding Labora-
tories, Wilmington, Massachusetts, USA), were randomly as-
signed to orally immunized or control groups. Animals were
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maintained with free access to food (Purina Mills, Inc., Rich-
mond, Indiana, USA) and either normal drinking water (6 m in
HC1, control) or a solution of 0.1% bovine gamma globulin
(BGG) in 6 mi HC1 (immunized) for six weeks [8, 26, 34, 35].
Then, after an initial collection of urine, all animals were
challenged with 1 mg BGG i.v. daily for three successive days.
After an additional two days, a second urine collection was
performed, and kidneys and blood samples were taken from
rats anesthetized with ether.
For more detailed study, 200 g male Lewis rats were used. A
total of 61 rats were orally immunized with BGG as described
above for eight weeks. An additional 22 rats were maintained as
nonimmune controls. At the completion of the continuous oral
immunization, all animals were challenged with BGG and urine
was collected from all rats as described above. Rats were
subsequently either sacrificed under ether anesthesia for sam-
pling of kidneys and blood, or used for hemodynamic studies
(below).
Inhibition of thromboxane
Randomly selected immunized or control rats were treated
with the thromboxane receptor antagonist SQ 29,548 (Squibb,
Princeton, New Jersey, USA), the thromboxane synthase in-
hibitor UK 38,485 (Pfizer, Sandwich, Kent, UK), or a combi-
nation of both agents. After the first 49 days of oral immuniza-
tion, a 120 m solution of SQ 29,548 in 120 mrvi TRIS, pH 8.2,
was prepared by evaporating the solvent from an ethanolic
solution of drug and buffer base and redissolving the residue in
water. Osmotic minipumps (Aiza Corp., Palo Alto, California,
USA) were loaded with the solution of SQ 29,548, or saline and
then implanted into the peritoneal cavity under Ketamine®
(Bristol Laboratories, Syracuse, New York, USA) anesthesia.
The pumps were designed to deliver 9 j.d/hr (14.4 mg/kg/day) for
two weeks. The UK 38,485 was given at 100 mg/kg/day for 10
days in two divided daily doses by intragastric intubation,
starting at 53 days of continuous oral immunization. Oral
immunization was maintained throughout the period of drug
treatment in both cases.
Urinalysis
Rats were housed singly in metabolic cages for 20 to 24 hours
with free access to water; food was withheld. After dipstick
examination with Hemastix® and Albustix® (Miles Laborato-
ries, Naperville, Illinois, USA), 10 ml of urine were centrifuged
at 500 x g for 10 minutes. The sediment was examined
microscopically for erythrocytes, and the supernatant re-cen-
trifuged at 2,000 x g for five minutes. Microhematuria was
considered present when more than 10 red cells on average
were observed per high-power field [25, 34]. Protein concentra-
tion was measured by sulfosalicylic acid-induced turbidity, and
protein excretion per 24 hours was calculated [22, 26].
Determination of serum antibody
At sacrifice, blood was drawn from the aorta and IgG and IgA
antibody to BGG were determined by an ELISA similar to
those previously described [8, 22, 26, 34, 35]. Ninety-six well
polystyrene plates (Maxisorp®, Nunc, Kamstrup, Denmark)
were coated with 10 j.tg/ml BGG in sodium carbonate-bicarbon-
ate buffer, pH 9.6, and incubated overnight at room tempera-
ture. Next, serum samples diluted 1:20 to 1:1280 in 1% BSA/
PBS were added (100 1.d/well) to duplicate wells. The plates
were incubated for two hours at room temperature. Finally,
peroxidase-conjugated mouse anti-rat IgA (Zymed Laborato-
ries, San Francisco, California, USA) or goat anti-rat IgG
(Jackson Immunochemicals, Bar Harbor, Maine, USA) were
applied (100 jd/well diluted 1:1,000 to 1:5,000 as required for
optimal detection) followed by 100 LIwel1 of a solution of
2,2-azino-di(3-ethylbenzthiazoline sulfonic acid; Zymed Labo-
ratories) in 0.1 M citrate buffer, pH 4.2, containing 0.03%
hydrogen peroxide. The green color developed by the peroxi-
dase was measured at 410 nm with an automated microplate
photometer (MR600, Dynatech, Alexandria, Virginia, USA).
The plates were washed three times with PBS/0.05% Tween 20
between each step. Titers (log2) were calculated by interpola-
tion into standard curves obtained from known sera serially
diluted in PBS.
Histological, immunohistochemical and ultrastructural
examination
At sacrifice, the upper poles of right kidneys from rats not
used for hemodynamic studies were divided into sections for
immersion fixation in 10% buffered formalin and for snap-
freezing in isopentane pre-chilled in liquid nitrogen [8, 22, 26,
34, 35]. Fixed tissue was embedded in Paraplast® (Fisher
Scientific, Pittsburgh, Pennsylvania, USA), sectioned at 2 jim,
and stained with periodic acid-Schiff. Coded sections were
examined by two observers with a bright-field light microscope.
Cryostat sections, 4 of frozen tissue were air-dried and
stained as previously described [8, 22, 26, 34, 35] with fluores-
cein-conjugated goat antibodies (all from U.S. Biochemicals,
Cleveland, Ohio, USA) specific for rat IgG, C3 or bovine IgG
(BGG antigen) or with a mouse anti-rat IgA (Zymed Laborato-
ries) followed by a fluoresceinated goat anti-mouse IgG not
cross reactive with rat IgG (U.S. Biochemicals). Coded sec-
tions were scored by two observers, using an epifluorescence
microscope, on a semiquantitative scale of 0 to 4+ [8, 22, 26,
34, 35]. Between 20 and 30 glomeruli were scored for each
reactant on each sample.
Cubes of cortex, 1 mm in each dimension, were immersion-
fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate, pH
7.5, overnight at 4°C, post-fixed in 1% osmium tetroxide, and
subsequently embedded in Spurr's epoxy. Silver sections (90
nm) were picked up on uncoated nickel grids, stained in uranyl
acetate and lead citrate, and examined as coded specimens in a
Philips 201C electron microscope, as previously described [8,
12, 13, 22, 26, 34, 35].
Glomerular eicosanoid synthesis
After histologic sampling, glomeruli were isolated from the
renal cortex of rats not used for hemodynamic studies by a
sequential graded sieving technique [22, 26]; more than 95% of
the particles in suspension were glomeruli by microscopic
examination. Glomeruli were incubated in Earle's Balanced
Salt Solution (EBSS) with 20 mivi HEPES with (stimulated) or
without (basal) added 3 M calcium ionophore (A23 187) for 30
minutes at 37°C with continuous agitation, and then centrifuged
at 500 >< g for 15 minutes. Protein content of glomerular pellets
was assayed by the Lowry method. The concentration of
prostaglandin E2 and thromboxane B2, the hydrolysis product
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that accounts for virtually all of the active thromboxane A2,
were determined in supernatants by radioimmunoassay [22, 26].
The concentrations of the eicosanoids were divided by the mass
of glomerular protein in the corresponding pellet, to express
eicosanoids as nglmg glomerular protein/30 minute incubation
period.
Glomerular hernodynamics
Randomly selected immunized and control rats were anes-
thetized with 0.5 to 0.6 ml Ketamine® intraperitoneally. Rats
were immobilized on a heating pad regulated to 37°C, and a
tracheostomy performed. A femoral artery and vein were
exposed, isolated and cannulated with microcatheters prepared
from polyethylene tubing; a polyethylene catheter was also
placed in the urinary bladder via a cystotomy. After the animal
was stabilized, an infusion of 3H-inuliri (250 pCi/mg, New
England Nuclear, DuPont Biotechnology Systems, Wilming-
ton, Delaware, USA) and 14C-para-aminohippurate (PAH, 230
pCi/mg, New England Nuclear) in 10 m sodium phosphate,
150 m sodium chloride, pH 7.6, was started and pumped at 1
mlfhr via the femoral vein cannula; the concentrations were
adjusted to deliver 1.6 tCiIhr 3H-inulin and 1.2 pCi/hr '4C-
PAH. After a 30-minute equilibration period, three urine col-
lections of 20 minutes each were obtained via the bladder
cannula, with arterial blood samples (100 d) being taken at the
mid-point of each urine collection. The entire urine volume and
a defined volume of serum from each period were counted for
3H and '4C with a liquid scintillation counter (Beckman, Ful-
lerton, California, USA). Blood, 0.2 ml, was sampled from the
renal vein after the last clearance period and counted to
compute PAH extraction, Inulin and PAH clearances were
calculated from the urine and blood radioactivities, and RPF
was calculated from the PAH extraction and clearance [22, 26].
GFR was taken as the inulin clearance. Glomerular filtration
fraction was calculated by dividing the maIm clearance by the
RPF.
Statistical analysis
All quantitative results were analyzed by Student's t-test (for
2 groups) or Fisher's protected t-test from analysis of variance
(for 3 groups). Distributions were evaluated by chi-squared
analysis, with Fisher's correction for small numbers applied.
Results
Pilot studies
As shown in Table 1, Lewis and Wistar rats proved to be high
IgA responders: orally immunized rats developed 39- and
9.5-fold increases in serum IgA anti-BGG after oral immuniza-
tion (both P < 0.001 vs. respective controls). Fischer and
Sprague-Dawley rats, by contrast, developed poor serum IgA
antibody responses (3.9- and 4.5-fold increases in IgA anti-BGG
vs. controls, P < 0.01). Lewis rats were also high IgG respond-
ers (36-fold increase) whereas the other strains had comparable
titers of IgG anti-BGG in serum (6- to 11-fold vs. the respective
control, all P < 0.001). Glomerular deposits paralleled serum
antibody titers. Orally immunized Lewis (87%) and Wistar
(8 1%) rats developed glomerular IgA immune deposits (mean
intensity 1.8+ and 1.5+ in Lewis and Wistar rats, respectively)
typically associated with IgG (1.4+, both strains), BGG antigen
Table 1. Serum antibody response in orally immunized rats
Strain
Immune
status
No. of
rats
Serum anti-
BGG antibody
titer (log2)
IgA IgG
Lewis Control
Immunized
Wistar Control
Immunized
Fischer Control
Immunized
Sprague-Dawley Control
Immunized
23
23
15
16
6
6
6
6
0 0
5.28a 5.18a
0 0
3.25a 345k
0 0
I.95 2.59a
0 0
2.l7a 3.ll
Data are titers referenced against the background optical densities
obtained with age-matched control serum from the same strain.
a 3.5, P < 0.001 by Fisher's protected t-test in analysis of
variance (all F's  13.2) compared to age-matched controls of the same
strain
(1.2+ and 1.5+, respectively) and C3 (0.8+ and 1.1+, respec-
tively) significantly more frequently than either nonimmune
Lewis or Wistar rats or orally immunized Fischer and Sprague-
Dawley rats (all  6.0; all P < 0.05, data not shown).
Features of the model
Previous studies of the regulation of mucosal immune re-
sponses in mice indicate that extension of the duration of oral
immunization beyond six weeks increases the ratio of IgA to
IgG antibodies due to onset of oral tolerance [35]. More
prolonged antigen exposure also enhances glomerular immune
deposits and the predominance of IgA. To increase the IgA
immune response and thereby intensify glomerular IgA deposi-
tion relative to IgG, we extended the duration of oral immuni-
zation from six to eight weeks. Since in the pilot studies Lewis
rats proved to be the best IgA responders, we focused on this
strain for further work. Lewis rats with IgAN after oral immu-
nization for eight weeks developed increased serum IgA (64-
fold) and IgG (16-fold) anti-BGG titers relative to nonimmune
controls (both P < 0.001; data not shown). Although the IgA
antibody titers were higher than in rats immunized for six
weeks, the IgG titers were somewhat lower.
Before systemic challenge, 68% of immunized rats and 14%
of controls had microhematuria ( = 9.8, P < 0.01, data not
shown). After i.v. challenge of all rats with BGG, microhema-
tuna was observed in 84% of immunized untreated but only
18% of nonimmunized control rats (,y2 = 13.7; P < 0.001).
Urinary protein excretion was no different in immunized rats
after challenge than in controls pre-challenge (4.83 0.46 vs.
5.61 0.73 mg/24 hr).
Immunized rats developed glomerular deposits of IgA (mean
intensity 2.8+), IgG (1.5+), C3 (1.5+) and BGG antigen (2.3+)
much more frequently and intensely than controls (all y2  13.7;
P < 0.005; Table 2, Fig. 1). The glomerular staining was
mesangial in all cases, and uniform among glomeruli within an
individual rat. The deposits of IgA and IgG observed in four of
the control rats was segmental in distribution and trace in
intensity, notably different from the intense deposits seen in the
immunized rats. Mild to moderate expansion of mesangial
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Table 2. Clinical and immunopathol gical findings in orally immunized Lewis rats
Group
No. of
rats
Microscopic
hematuriaa
Glomerular immunofiuorescencea
EM depositsaIgA IgG C3 BGG
Control' 22 18 18 18 0 5 0
IgAN" 25 84" 84C 80" 64C 68" 100"
IgAN + UK + SQ 20 15 80" 75 65" 70" 88"
IgAN + UK 8 0 75 88" 50" 63"
IgAN + SQ 8 25 88" 75" 63" 75d
a Data are percent rats positive; electron microscopy (EM) data based on 8 randomly selected rats per groupb These groups each included 7 rats with osmotic minipumps implanted to deliver normal saline (drug vehicle) as a control for surgery and added
fluid volume. There were no differences between rats with pumps compared to the 15—18 rats in the same group not given pumps; hence, data were
pooled.
 12.3, P < 0.001 compared to controls
 7.4, P < 0.01 compared to controls
 5.6, P < 0.05 compared to controls
IgA lgG C
CON
1MM
Fig. 1. immunofluorescence micrographs reveal the pattern of deposition of IgA, IgG and C3 (C) in representative glomerulifrom rats maintained
as age-matched controls (CON) or continuously orally immunized (1MM) for 8 weeks with 0.1% BGG. Note that granular staining for all reactants
(IgA> IgG) lies within mesangial areas in immunized rats. Although no staining was present in 82% of controls, 18% had weak segmental staining,
easily discriminated from the heavier deposition in immunized rats. Deposition of BGG (not shown) was similar. The fluorescence for C3 in the
control (upper right) is confined to Bowman's capsule and is a usual finding in normal rats. (All 350x)
matrix, accompanied by mild segmental mesangial hypercellu- discrete electron dense deposits confined to the mesangium,
larity was observed in 88% of immunized rats, but only in 9% of associated with increased organelle content within mesangial
controls ( = 21.5, P < 0.001, Fig. 2). In addition, all cells (Fig. 3); these features were not observed in control rats
immunized rats had numerous, moderately large 200 to 400 nm, ( = 12.3, P < 0.01, Table 2). There was no evidence of
cJ..
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Fig. 2. Light micrographs of rats orally immunized and parenterally challenged with BGG (A) reveal mild to moderate increases in PAS-positive
mesangial matrix (arrows) and equivocal to mild increased mesangial cellularüy, compared to nonimmune controls (B). Immunized and challenged
rats treated with the combined anti-thromboxane drug regimen (C) reveal more modest accumulations of PAS-positive mesangial matrix than in
untreated rats. (PAS stain, 450x)
leukocytic infiltration or platelet accumulation, podocyte
broadening, endocapillary or extracapillary proliferation, ne-
crosis, or glomerulosclerosis in any rat. These features closely
emulate the most prevalent pattern of histologic changes among
some 2,000 patients (1—4].
Glomeruli isolated from immunized IgAN rats produced
more thromboxane (Table 3), whether stimulated with iono-
phore A23 187 (2.14 0.23 ng/mg glomerular protein) or unstim-
ulated (0.93 0.24 nglmg glomerular protein) than those from
nonimmunized control rats (1.27 0.22, 0.33 0.16, respec-
tively, both P < 0.01). In contrast, glomeruli from both groups
produced the same amount of prostaglandin E2 (Table 3).
Moreover, GFR (2.0 0.13 ml/min) and RPF (8.7 0.50
mi/mm) were significantly reduced (P < 0.01) compared to
nonimmune controls (2.5 0.14 and 11.0 0.78), whereas the
glomerular filtration fraction was unchanged (0.228 0.007 vs.
0.228 0.011; Fig. 4).
Modulation of glomerular function by inhibition of
thromboxane
Some rats were treated with a thromboxane receptor antag-
onist, a thromboxane synthase inhibitor, or both. Either of
these drugs alone, or the combination of both, reduced the
incidence of hematuria to background levels (Table 2) without
affecting serum antibody titers (data not shown), or glomerular
immune deposits (Table 2). The combination of drugs did not
influence the low-level background hematuria or glomerular
immune deposits in nonimmune controls (data not shown). The
thromboxane synthase inhibitor, with or without added recep-
tor antagonist, reduced thromboxane synthesis relative to the
untreated immunized rats, whereas prostaglandin E2 synthesis
increased (all P < 0.01; Table 3).
To determine the potential influence of glomerular thrombox-
ane synthesis on glomerular hemodynamics, we elected to
study rats given both drugs in combination. The combined
anti-thromboxane drugs corrected RPF in immunized rats to a
level (10.3 0.50mI/mm) not significantly different from that in
nonimmune controls (Fig. 4). However, the decrement in GFR
seen in untreated IgAN rats was intensified by anti-thrombox-
ane drugs (1.61 0.09 ml/min), and, of course, glomerular
filtration fraction was substantially reduced (0.157 0.005)
from the level seen in both control and untreated IgAN rats (P
< 0.001; Fig. 4). The combination of drugs did not influence
RPF (11.3 1.0), GFR (2.6 0.3) or glomerular filtration
fraction (0.231 0.009) in six normal rats (all P = NS vs.
control, data not shown).
Discussion
Regulation of the mucosal immune response and the balance
of antibody classes is a complex process [35—40]. Although
most of our limited knowledge of regulation of mucosal immune
responses, like immune responses in general, has been gleaned
from study of mice and humans, the conceptual framework also
applies to rats to the extent that this species has been consid-
ered [39, 40]. Hence, it is not surprising, as shown here, that
some rat strains (Lewis, Wistar) are much better IgA respond-
ers after oral immunization than others (Sprague-Dawley,
Fischer). Our data show, furthermore, that when such high-IgA
responder rats are chronically orally immunized and systemi-
cally challenged with antigen, they develop glomerular mesan-
gial immune deposits that include predominantly IgA antibody.
These data recapitulate earlier observations in mice which
demonstrate that the propensity for developing mesangial IgA
immune deposits after protracted oral immunization is related
to a strain-dependent capacity to mount an IgA immune re-
sponse [8, 91.
In the high-IgA responder Lewis rats, the resultant glomeru-
lonephritis closely resembles that in similarly immunized mice
on the one hand and patients with IgAN on the other [1—9, 34,
35]. Clinically, immunized rats develop microhematuria with no
proteinuria. Pathologically, a mild to moderate mesangial ex-
pansion by matrix and cells is seen, associated with mesangial
but not capillary electron dense deposits, with IgA as the
predominant 1g. This constellation represents the most preva-
lent pattern of IgAN in patients [1-4].
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Fig. 3. Ultrastructural examination of rats
orally immunized and parenterally challenged
with BGG reveals irregular electron dense
deposits (arrows) in mesangial and
paramesangial sites, without deposits in the
capilla,y walls (A). There is no broadening of
foot-processes, nor leukocyte or thrombocyte
infiltrate (not shown). In many areas (B)
increased organelle content and dense bodies
(arrows) are evident within mesangial cells.
These features were not present in controls,
but were present in nearly all immunized rats
given the combined anti-thromboxane drug
regimen (not shown, cf Table 2). (A 13,090x;
B l1,900x)
Glomerular synthesis of vasoactive eicosanoids revealed an
unusual pattern in this model of IgAN: vasoconstrictor throm-
boxane was doubled, with no change in opposing prostaglandin
E2 synthesis. In other experimental glomerulonephritides stud-
ied to date, any increase in thromboxane was paralleled by a
proportionate or even greater increase in prostaglandin E2 once
nephritis was well established [18—32]. During the acute, eva-
nescent phase of immune complex nephritis an increase in
thromboxane relative to prostaglandin E2 is transient [18, 20,
27, 28, 30—32]. In the IgAN rats described in this paper, altered
glomerular function was evidenced by hematuria, without pro-
teinuria. In glomerulonephritic rats studied previously [18—20,
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Table 3. Eicosanoid synthesis in vitro by glomeruli isolated from rats
Group
No. of
rats
PGE2 TxB2a
A23187-
stimulated Basal
A23187-
stimulated Basal
Immunized
Immunized + both drugs
Control
10
12
11
5.82 0.70
8.29 0.5l''
4.86 0.57
0.54 0.18
1.06 0.30c
0.72 0.24
2.14 0.23!)
0.82 0.19"°
1.27 0.22
0,93 + 024b
0.21 0.19c
0.33 0.16
a Data are mean (± SD) ng eicosanoid/mg glomerular protein/30 mm incubation
Significantly different (P < 0.01) from control group by Fisher's protected t-test in ANOVA (F  7.74)
Significantly different (P < 0.01) from untreated immunized group by Fisher's protected t-test in ANOVA (F  7.74).
Group
Fig. 4. Renal hemodynamic parameters in normal controls rats, orally
immunized rats with IgAN, and rats with IgAN treated with a throm-
boxane synthase inhibitor (UK 38,485) and a thromboxane receptor
antagonist (SQ 29,548). The proportionate decreases in RPF (D) and
GFR () in rats with IgAN relative to controls (* < 0.01) result in a
normal OFF. Treatment of IgAN with anti-thromboxane drugs restores
RPF, but not GFR, resulting in a reduced GFF (*p < 0.01). Adminis-
tration of this combined drug regimen to normal rats does not affect
glomerular hemodynamics.
22—32], proteinuria was the clinical hallmark of disease, and no
hematuria was observed. Hence, at least in rats, microhema-
tuna may be associated with a glomerular eicosanoid and
hemodynamic pattern distinct from that associated with heavy
proteinuria. However, in toxic nephrosis induced by adriamy-
cm, a pattern of glomerular eicosanoids similar to that observed
here was associated with heavy proteinuria [331; hematuria was
not evaluated in that study. As in previous work, ionophore
added to the incubation medium increased PGE2 and TxA2
synthesis in approximately equal, generally 3- to 5-fold, propor-
tion [27, 28, 31, 32]. All the work to date suggests that activation
of phospholipase A2, while certainly a contributor to total
eicosanoid mobilization, is not an important determinant of the
proportion of constrictor versus anti-constrictor eicosanoid
production.
Immunized rats with IgAN also had significant (20%) and
proportionate reductions in RPF and GFR. We postulate that
these decrements in glomerular hemodynamics occur conse-
quent to a disproportionate increase in vasoconstrictor (throm-
boxane) eicosanoids versus the constant level of anti-constric-
tor (PGE2) release within glomeruli. The effect of a thromboxane
synthase inhibitor and a thromboxane receptor antagonist in
combination on glomerular hemodynamics supports a functional
significance of the alterations in glomerular eicosanoid synthesis.
Despite the fact that these agents did not influence antibody titers
or glomerular immune deposits, the combination of these drugs
dramatically reduced hematuria and glomerular thromboxane syn-
thesis, and increased glomerular prostaglandin production. As
would be expected from a decrease in vasoconstrictor and an
increase in anti-constrictor eicosanoids, RPF in treated IgAN rats
increased. On the other hand, GFR did not normalize, and
actually decreased. Since the combination of drugs did not affect
hemodynamics in normal rats, it would appear that inhibition of
the effects of the increased thromboxane, rather than some other
direct effect of one or both of the drugs, increased RPF in the
diseased rats.
A variety of explanations for the relationship between gb-
merular eicosanoids and hemodynamics can be conceived. The
simplest would be that glomerular thromboxane and prostaglan-
din strongly affect RPF [19, 20, 23], but that other factors also
come into play in the regulation of glomerular filtration. We
suggest that in rats with IgAN, efferent arterioles constrict in
response to increases in the glomerular thromboxane/prosta-
glandin ratio, reducing RPF and increasing glomerular capillary
pressure. However, the unchanged filtration fraction suggests
that any increase in glomerular capillary pressure is opposed by
a proportionate reduction in LpA, perhaps due to mesangial
contraction [19]. In our studies, combined inhibition of throm-
boxane synthesis and antagonism of thromboxane receptors
corrected RPF to normal. The fact that the filtration fraction
decreased substantially after such treatment suggests that the
decrement in LpA is an independent glomerular response to
immune injury. This interpretation must remain tentative until
additional experiments measuring glomerular hemodynamic
responses can be performed. Micropuncture studies can di-
rectly address these issues, but such studies would be ham-
pered because rat strains with subcapsular glomeruli accessible
for micropuncture are not high IgA responders after oral
immunization.
Hematuria may be partly a consequence of increased glomer-
ular capillary pressure and concurrent glomerular contraction.
Diapedesis of erythrocytes through capillary basement mem-
branes is well known, and erythrocytes can with suitable
pressure (—10 mm Hg) penetrate 100 to 1,000 nm rigid pores in
a stainless steel disk [41—43]. However erythrocytes penetrate
glomerular basement membranes, increased intracapillary pres-
sure likely contributes. While it is conceptually feasible for
hematuria to be simply an expression of increased glomerular
capillary pressure, the amelioration of hematuria by thrombox-
ane antagonists is likely complex. Proper explanation must
await refinements in ability to assess glomerular permeability to
erythrocytes. Whatever the mechanisms, the data presented
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here offer preliminary evidence implicating a pathophysiologic
role for thromboxane, or increased TxA2 in proportion to
PGE2, in IgAN. Indeed, the ratio of TxA2 to PGE2 correlated
with the severity of hematurja (r = 0.35, F = 4.33, P < 0.05),
although neither TxA2 or PGE2 synthesis alone correlated
significantly.
The source of the increase in thromboxane is obscure.
Leukocytic or thrombocytic glomerular infiltrates, potential
sources of TxA2, are evident neither in this rat model, nor in the
vast majority of human cases of IgAN [1—4]. Several distinct
immune agonists, including immune complexes, promote in-
creased TxA2 synthesis by and contraction of mesangial cells in
culture, but typically there is at least some increase in PGE2 as
well [44—48]. Another possibility would be an increase in the
synthesis of TxA2 by normal numbers of glomerular platelets
and/or monocytes on a per cell basis. The identification of the
cellular source of the increased thromboxane must also await
further investigation. The stimuli for increased glomerular
thromboxane synthesis and the biochemical pathways by which
these stimuli are transduced are also of interest. However,
control of these responses is enigmatic in IgAN, as in glomer-
ulonephritis in general.
In summary, our adaptation of a mouse model of IgAN to rats
supports its general relevance across species, including hu-
mans. In addition, it provides an opportunity to explore the
relationships among glomerular hemodynamics, altered glomer-
ular function including hematuria, eicosanoid synthesis, and
perhaps glomerular contraction in IgAN. Additional experimen-
tal work, particularly with micropuncture systems, long-term
study to determine if glomerular sclerosis ensues, and manipu-
lations designed to probe the mechanisms of altered glomerular
hemodynamics and function can proceed, perhaps in parallel
with noninvasive studies of IgAN patients, to assess the rele-
vance of the experimental work to the clinical disease. The
unusual glomerular eicosanoid synthetic pattern in this model
may also prove useful for understanding the regulation of
glomerular arachidonate metabolism and its influence on gb-
merular function.
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